Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference

Rhea-AI Summary

Acumen Pharmaceuticals (NASDAQ: ABOS) said management will participate in a fireside chat at the Stifel Healthcare Conference on Tuesday, Nov. 11, 2025 at 4:40 p.m. ET. The company is a clinical-stage biopharmaceutical developer focused on therapeutics targeting toxic soluble amyloid beta oligomers for Alzheimer’s disease. A live webcast will be available via the company Investors page and archived for 90 days.

News Market Reaction

-11.01%

1 alert

-11.01% News Effect

-$16M Valuation Impact

$126M Market Cap

0.1x Rel. Volume

On the day this news was published, ABOS declined 11.01%, reflecting a significant negative market reaction. This price movement removed approximately $16M from the company's valuation, bringing the market cap to $126M at that time.

Data tracked by StockTitan Argus on the day of publication.

NEWTON, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, announced today that management will participate in a fireside chat at the Stifel Healthcare Conference on Tuesday, Nov. 11, 2025, at 4:40 p.m. ET.

The live webcasts may be accessed under the Investors tab on www.acumenpharm.com and will be archived for 90 days.

About Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD). Acumen’s scientific founders pioneered research on AβOs, which a growing body of evidence indicates are early and persistent triggers of Alzheimer’s disease pathology. Acumen is currently focused on advancing its investigational product candidate, sabirnetug (ACU193), a humanized monoclonal antibody that selectively targets toxic soluble AβOs, in its ongoing Phase 2 clinical trial ALTITUDE-AD (NCT06335173) in early symptomatic Alzheimer’s disease patients, following positive results in its Phase 1 trial INTERCEPT-AD. Acumen is also investigating a subcutaneous formulation of sabirnetug using Halozyme’s proprietary ENHANZE^® drug delivery technology. Acumen is also collaborating with JCR Pharmaceuticals to develop an Enhanced Brain Delivery (EBD™) therapy for Alzheimer’s disease utilizing a transferrin-receptor-targeting blood-brain barrier-penetrating technology. The company is headquartered in Newton, Mass. For more information, visit www.acumenpharm.com.   

Investors:
Alex Braun
abraun@acumenpharm.com

Media: 
AcumenPR@westwicke.com 

FAQ

When will Acumen Pharmaceuticals (ABOS) present at the Stifel Healthcare Conference?

Acumen will participate in a fireside chat on Tuesday, Nov. 11, 2025 at 4:40 p.m. ET.

How can investors watch Acumen Pharmaceuticals (ABOS) at the Stifel Healthcare Conference?

The event will be live webcast and accessible under the Investors tab at www.acumenpharm.com.

Will the Acumen Pharmaceuticals (ABOS) Stifel webcast be available after the event?

Yes, the webcast will be archived for 90 days on the company's Investors page.

What will Acumen Pharmaceuticals (ABOS) likely discuss at the Stifel Healthcare Conference?

Management will discuss the company's clinical development of therapeutics targeting soluble amyloid beta oligomers for Alzheimer's disease.

Is the Acumen Pharmaceuticals (ABOS) presentation at Stifel open to the public?

The live webcast is publicly accessible via the company's Investors page; no registration details were specified.